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ABSTRACT
Objective To examine variation in the management of
prostate cancer in patients with different socioeconomic
status.
Design Survey using UK regional cancer registry data.
Setting Regional population based cancer registry.
Participants35171patientsaged≥51withadiagnosisof
prostate cancer, 1995-2006.
Main outcome measures Use of radiotherapy and radical
surgery.Socioeconomicstatusaccordingtofifthsofsmall
area deprivation index.
ResultsOvernineyearsofthestudy,informationonstage
at diagnosis was available for 15916 of 27970 patients
(57%).Duringthestudyperiod,theproportionofpatients
treated with radiotherapy remained at about 25%, while
use of radical surgery increased significantly (from 2.9%
(212/7201) during 1995-7 to 8.4% (854/10211) during
2004-6, P<0.001). Both treatments were more commonly
used in least deprived compared with most deprived
patients (28.5% v 21.0% for radiotherapy and 8.4% v
4.0% for surgery). In multivariable analysis, increasing
deprivation remained strongly associated with lower
odds of radiotherapy or surgery (odds ratio 0.92 (95%
confidenceinterval0.90to0.94),P<0.001,and0.91(0.87
to 0.94), P<0.001, respectively, per incremental
deprivation group). There were consistently concordant
findings with multilevel models for clustering of
observations by hospital of diagnosis, with restriction of
the analysis to patients with information on stage, and
withsequentialrestrictionoftheanalysistodifferentage,
stage, diagnosis period, and morphology groups.
Conclusions After a diagnosis of prostate cancer, men
from lower socioeconomic groups were substantially less
likely to be treated with radical surgery or radiotherapy.
The causes and impact on survival of such differences
remain uncertain.
INTRODUCTION
In the United Kingdom, prostate cancer is currently
the most common malignancy in men. Its incidence
has been increasing, particularly since the late 1980s
and early 1990s,
1 and is socioeconomically patterned.
In the late 1990s and earlier in the present decade the
incidence was about 20-40% greater in least deprived
individuals.
23Five year relative survival hasimproved
substantiallyoverthepast20yearsandwasabout80%
earlyinthe2000s.
4Likeincidence,survivalfrompros-
tate cancer is also socioeconomically patterned, with
an absolute gap as high as 7% in five year relative sur-
vivalbetweentheleastandmostdeprivedindividuals.
5
Socioeconomic inequalities in survival from prostate
cancer have also been described in New Zealand
6 and
Denmark.
7
Socioeconomic differences in use of testing for pros-
tatespecificantigenarethoughttobepartlyresponsible
for both higher incidence and increased survival in less
deprived individuals.
8 According to this hypothesis,
higher uptake of screening for prostate specific antigen
in more affluent men leads to diagnosis of a relatively
higherproportionofearlierstage(andbetterprognosis)
prostatecancer,whichinturncontributestogreatersur-
vival of more affluent patients. Although there is some
evidence in support of this hypothesis,
910because pros-
tatespecificantigentestingcantakeplaceinbothhospi-
talandprimarycaresettings,aswellasinthepublicand
the private healthcare sector, directly examining the
degreeofdifferential test uptakebetween menofdiffer-
ent socioeconomic status is fraught with practical diffi-
culties.Eveniftherearedifferencesintheproportionof
(early stage) prostate cancer detected by screening in
menfromdifferentsocioeconomicgroups,itisalsopos-
sible that some of the observed inequalities in survival
reflect socioeconomic variation in management.
8
Optimal treatment for early stage prostate cancer is
currently uncertain. The main management options
comprise radical surgery, external beam radiotherapy,
or active monitoring with biochemical follow-up.
11
Which of these strategies is most effective is not known
c ur r e n t l y ,a n dam a j o rr a n d om i s e dc on t r o l l e dt r i a lc om -
paring active monitoring with radiotherapy and with
radical surgery is not expected to report its findings
before 2012.
12 In addition, a range of other inter-
ventional procedures, including cryotherapy, high
intensityfocusedultrasound(HIFU),andbrachytherapy
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also been proposed.
11 Evidential uncertainty about opti-
mal management could make socioeconomic variation
in management more likely.
13
We examined whether socioeconomic variation in
management exists and quantified the potential size
of any such healthcare differences.
METHODS
Data
We obtained anonymised information on patients
fromtheEasternCancerRegistrationandInformation
Centre (ECRIC), one of the eight English population
based cancer registries, covering a population of 5.5
million. Incident cases of prostate cancer were defined
as those with ICD-10 (international classification of
diseases, 10th revision) site codes C61. Using relevant
ICD-O morphology codes, we defined two groups:
adenocarcinoma (M8140-3) and “unspecified” pros-
tate cancer, comprising “carcinoma” (8010-3) and
“neoplasm malignant” (8000-3). Patients with other
(rare) histological types were excluded from further
analysis. Information relates to residents of the East
of England Government Office region aged >50 with
a diagnosis in 1995-2006 (this age restriction excluded
246patientsaged≤50).Thelatterstudyyear(2006)was
the most recent study year for which data were avail-
able at the time of the analysis. We chose 1995 as the
earlieststudyyeartoprovidealongenoughperiodthat
would also encompass recent healthcare policy initia-
tives,suchastheNHSCancerPlan(published2002)and
the publication of Improving Outcomes Guidance in Uro-
logical Cancers (published 2002).
When available, information on stage at diagnosis
related to the fifth edition of the tumour, node, meta-
stases (TNM) classification (stages I to IV).
14 Based on
registration information, Clement Brown (medical
director and consultant clinical oncologist, Eastern
Cancer Registration and Information Centre) derived
information on staging for each case.
Socioeconomic status was assigned with the depriva-
tion score of postcode of residence (index of multiple
deprivation 2004 lower super output area score).
15 The
index is a UK census based (2001) small area statistic
measuring different domains of deprivation. A lower
super output area typically comprises five coterminous
(having a common boundary) and sociodemographi-
cally similar output areas (the lowest small area with
aggregatedcensusinformation)andhasabout1500resi-
dents.This“homogenous”andlowlevelofaggregation
minimises the potential for misattributing individual
socioeconomic status by using the “average” socioeco-
nomic profile of a greater sample of individuals.
16 We
usedfifthsoftheEnglishdistributionoflowersuperout-
put area deprivation scores in our analyses (group 1
(least deprived) to 5 (most deprived)).
Registry staff collect and code information on treat-
ment over at least a six month period from diagnosis.
This includes surgical treatments, classified by the
Office for Population Censuses and Surveys (fourth
revision, OPCS 4) system,
17 and radiotherapy.
Concordant with previous research, radical surgery
(hereafter referred to as “surgery”) treatment status
was defined as codes M611-9 (open excision of
prostate),
18 and the definition for radiotherapy treat-
ment included external beam radiotherapy and
brachytherapy.
19 Of all patients, 205 (0.6%) were trea-
ted by both radiotherapy and surgery. We assumed
that the initial clinical management in those patients
was more likely to be surgical, and we therefore
included such patients in the “surgery” group.
19 No
information was available about treatment intent nor
about comorbidity status.
Analysis
All analyses were carried out with Stata software (Sta-
taCorp, College station, TX, USA). We used binary
logistic regression models to examine whether stage
ascertainment and advanced stage (defined as stages
III-IV) at presentation differed by diagnosis period,
age, and deprivation. We described the proportion of
patientstreated with radiotherapy and withsurgeryby
diagnosis period (1995-7, 1998-2000, 2001-3, and
2004-6), age group (51-60, 61-70, 71-80, >80), and
deprivation group (1-5). We also examined bivariate
associations between deprivation and all of age
group, diagnosis period, morphology, and stage.
Theeffectofeachvariablecategoryonthe probabil-
ity of radiotherapy or surgery was initially examined
by multivariable logistic regression models, adjusted
for age, deprivation, diagnosis period, and morphol-
ogy. We derived odds ratios denoting the probability
of treatment for each deprivation group using the least
deprived group as reference and, subsequently, enter-
ing deprivation group (1-5) as a continuous variable in
the same model. The odds ratios obtained from the
latter models denote the change in odds ratio by mov-
ingfromonedeprivationgrouptotheoneimmediately
more deprived.
Subsequently, to take into account possible cluster-
ing (of patients from different deprivation groups and
with different treatment patterns within different hos-
pitals of diagnosis) we used multilevel mixed effects
logisticregressionmodelswitharandomeffectforhos-
pitalofdiagnosis.ThextmelogitcommandinStatawas
used to fit two separate models for the binary outcome
variablesofsurgeryandradiotherapytreatmentstatus.
Adjustmentwasmadeforallothervariablesusedinthe
non-hierarchicalmodels(asabove)—thatis,individual
level fixed effects were included in the multilevel
model for age group, deprivation fifth, diagnosis per-
iod, and morphology.
After complete case analysis, in which we did not
account for stage, we repeated multivariable logistic
regression analyses separately for cases with stage
information with adjustment for stage (both for the
non-hierarchical and the multilevel models). In addi-
tion, we repeated the analysis by sequentially stratify-
ingallmodelstopatientsaged≤70andthoseaged>70
(twoagegroups×twotreatments×“all”/stagedcases=
eight models); patients with early (I-II) and advanced
(III-IV)stage(twostagegroups×twotreatments=four
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during 2001-6 (two periods × two treatments × “all”/
staged cases = eight models); and adenocarcinoma or
“unspecified” tumour type (two tumour groups × two
treatments×“all”/stagedcases=eightmodels),produ-
cing a set of 28 additional odds ratios and correspond-
ing significance levels for the deprivation effect of
either treatment.
RESULTS
Out of a total of 35353 patients, 182 (0.5%) had rare
types of prostate cancer, leaving 35171 patients for
further analysis, of whom 29628 (84.2%) had adeno-
carcinoma and 5543 (15.7%) had tumours with unspe-
cified morphology (fig 1). Overall, stage information
was available for 16020 (45.5%), of whom 305 (1.9%),
11269 (70.3%), 1675 (10.5%), and 2771 (17.3%) were
diagnosedatstagesI,II,III,andIV,respectively.Dur-
ing1995-7,informationonstagewasavailableforonly
104 (1.4%)becausesystematicstageregistrationbegan
in later years. For this reason, when we restricted the
analysis to patients with information on stage, we used
data only from the nine year period 1998-2006, with
stage information for that period being available for
15916 of 27970 patients (56.9%).
Ascertainment of stage was not associated with
deprivation (table 1), but more deprived patients
were significantly more likely to have been diagnosed
with advanced (that is, stage III-IV) disease.
The proportion of patients treated by surgery in-
creased significantly over time, from 2.9% (212/7201)
during 1995-7 to 8.4% (854/10211) during 2004-6
(P<0.001,table 2).Wefoundsimilarincreasingtrends
amongpatientswithinformationonstage(during1998-
2006) though not significantly(P=0.318). Use ofradio-
therapyremainedstableataround25%throughoutthe
studyperiod,anditwassimilarlystableovertimeamong
patients with stage information.
Thereweresmallbutsignificantdifferencesbetween
patients from different deprivation groups. On aver-
age, more deprived patients were relatively older and
weremorecommonlydiagnosedinearlieryearsofthe
Men with prostate cancer, 1995-2006 (n=35 599)
Included in analysis adjusted
for stage (n=15 916, 57% of
patients diagnosed in 1998-
2006 with stage information)
Excluded because aged ≤50 (n=246)
Included (n=35 353)
Included in analysis (n=35 171)
Excluded because of rare tumour type (n=182)
Patients from 17 hospitals
included in multi-level
analysis adjusted for hospital
level clustering (n=29 805,
85% of all patients)
Fig 1 | Flow chart of study population and analysis groups
Table 1 |Associations between completeness of ascertainment of stage and “advanced stage” at presentation (defined as stages III-IV) and other variables in
men with prostate cancer, 1998-2006
Variable and
categories All patients
Patientswithstage
information
(% of all patients)
Predictors of completeness of stage
ascertainment
Patients with
stage III-IV
(% of all cases
with stage
information)
Predictors of advanced stage (III-IV)
Odds ratio (95% CI)* P value* Odds ratio (95% CI)* P value*
Diagnosis period (years):
1998-2000 7899 2697 (34.1)
2.58 (2.50 to 2.67) <0.001
865 (32.1)
0.86 (0.82 to 0.90) <0.001 2001-3 9860 5297 (53.7) 1487 (28.1)
2004-6 10 211 7922 (77.6) 2043 (25.8)
All 27 970 15 916 (56.9) —— 4395 (27.6) ——
Age group (years):
51-60 2632 1570 (59.7)
0.88 (0.87 to 0.91) <0.001
391 (24.9)
1.15 (1.10 to 1.19) <0.001
61-70 8574 5085 (59.3) 1367 (26.9)
71-80 11 156 6364 (57.0) 1617 (25.4)
>80 5608 2897 (51.7) 1020 (35.2)
All 27 970 15 916 (56.9) —— 4395 (27.6) ——
Deprivation group:
1 (affluent) 7235 4002 (55.3)
0.99 (0.97 to 1.01) 0.277
997 (24.6)
1.06 (1.03 to 1.09) <0.001
2 7716 4557 (59.1) 1303 (28.2)
3 6769 3999 (59.1) 1158 (28.7)
4 4753 2479 (52.2) 738 (29.4)
5 (deprived) 1497 879 (58.7) 250 (28.2)
All 27 970 15 916 (56.9) —— 4395 (27.6) ——
*From binary logistic regression models (stage ascertainment v no ascertainment; and advanced stage v non-advanced stage, respectively) with diagnosis period, age group, and deprivation
group entered as continuous variables in respective, otherwise unadjusted, models. Odds ratios denote increase in probability of outcome of interest (either completeness of stage
ascertainment or advanced stage) derived by moving from one ordinal category to one immediately higher—for example, by moving from diagnosis period 1998-2000 to diagnosis period
2001-3, or by moving from 2001-3 to 2004-6, etc. P values from these models serve as test for linear trend.
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more advanced stage (table 3).
Radiotherapy and surgery were more commonly
used in less deprived patients. Among patients in
deprivation groups 1 to 5 the proportion treated by
radiotherapy was 28.5% (2560/8977), 26.6% (2550/
9597), 23.6% (2010/8510), 22.2% (1358/6119), and
21.0%(413/1968),respectively,andforsurgerythefig-
ures were 8.4% (757/8977), 6.8% (650/9597), 6.5%
(551/8510), 5.2% (319/6119), and 4.0% (78/1968)
(table 2). Use of surgery decreased continually with
increasing age, while use of radiotherapy increased
with age up to age 70 and decreased thereafter. Treat-
mentpatternsfordeprivationgroupandageweresimi-
lar among patients with information on stage. Among
such patients, in those treated with surgery, 1% (19/
1275), 70% (891/1275), 26% (336/1275), and 2% (27/
1275) had stage I, II, III, and IV disease, respectively.
In patients treated with radiotherapy, the values were
1% (30/4239), 68% (2877/4239), 11% (486/4239), and
20% (846/4239).
Inmultivariableanalysis,higherdeprivationwassig-
nificantly associated with lower odds of either radio-
therapy (odds ratio 0.92, 95% confidence interval
0.90 to 0.94, P<0.001) or surgery use (0.91, 0.87 to
0.94, P<0.001) (table 4 and figs 2 and 4). Associations
were similaramongpatientswithinformation onstage
(table 4 and figs 3 and 5). Older age was significantly
associated with lower probability of use of either treat-
ment. Diagnosis later in the study period was
significantly associated with higher probability of sur-
gery and lower probability of radiotherapy.
Multilevel model analysis (at the level of hospital of
diagnosis) included 29805 of 35171 patients (84.7%)
diagnosed in any of the 17 East of England NHS Hos-
pitalTrusts(rangeofnumberofpatientsbytrust744to
3793). This analysis re-affirmed the significant socio-
economic treatment patterns observed in non-hier-
archical modelling, both in relation to “all” and in
relation to “staged” cases (table 5).
Moreover, we compared the proportion of patients
treated by surgery or radiotherapy in each hospital by
deprivation group (that is, the least and one but least
Table 2 |Proportion of patients treated by radiotherapy or radical surgery by basic characteristics for all men with prostate cancer, 1995-2006 (n=35 171),
and patients with stage information, 1998-2006 (n=15 916)
Variable and
categories All cases
Cases with stage
information
Radiotherapy Surgery
All cases
Cases with stage
information All cases
Cases with stage
information
No (%) P value* No (%) P value* No (%) P value* No (%) P value*
Diagnosis period (years):
1995-7 7201 — 1678 (23.3)
<0.001
—— 212 (2.9)
<0.001
——
1998-2000 7899 2697 2073 (26.2) 752 (27.9)
<0.001
514 (6.5) 167 (6.2)
0.318 2001-3 9860 5297 2748 (27.9) 1532 (28.9) 775 (7.9) 423 (8.0)
2004-6 10 211 7922 2392 (23.4) 1955 (24.7) 854 (8.4) 683 (8.6)
All periods 35 171 15 916 8891 (25.3) — 4239 (26.6) — 2355 (6.7) — 1273 (8.0) —
Age group (years):
51-60 3051 1570 1092 (35.8)
<0.001
547 (34.8)
<0.001
780 (25.6)
<0.001
447 (28.5)
<0.001
61-70 10 460 5085 4117 (39.4) 2032 (40.0) 1392 (13.3) 748 (14.7)
71-80 14 142 6364 3179 (22.5) 1441 (22.6) 172 (1.2) 76 (1.2)
>80 7518 2897 503 (6.7) 219 (7.6) 11 (0.3) 2 (0.1)
All ages 35 171 15 916 8891 (25.3) — 4239 (26.6) — 2355 (6.7) — 1273 (8.0) —
Deprivation group:
1 (affluent) 8977 4002 2560 (28.5)
<0.001
1196 (29.9)
<0.001
757 (8.4)
<0.001
384 (9.6)
0.001
2 9597 4557 2550 (26.6) 1291 (28.3) 650 (6.8) 369 (8.1)
3 8510 3999 2010 (23.6) 982 (24.6) 551 (6.5) 321 (8.0)
4 6119 2479 1358 (22.2) 570 (23.0) 319 (5.2) 163 (6.6)
5 (deprived) 1968 879 413 (21.0) 200 (22.8) 78 (4.0) 36 (4.1)
All groups 35 171 15 916 8891 (25.3) — 4239 (26.6) — 2355 (6.7) — 1273 (8.0) —
*P values from binary logistic regression models (treatment v no treatment) adjusting for variable of interest. For diagnosis period and deprivation group, adjustment also made for age
group. P values from these models serve as test for linear trend—that is, for significance (or lack of significance) of differences in treatment use when moving from one ordinal category to
one immediately higher—for example, by moving from diagnosis period 1995-1997 to diagnosis period 1998-2000.
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Fig 2 | Percentage of all patients with prostate cancer treated
by radiotherapy and odds ratio of use of radiotherapy by
deprivation group (odds ratios and 95% confidence intervals
adjusted for age, diagnosis period, and morphology)
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relativelymostdeprivedgroups(3,4,and5).Forradio-
therapy there was lower use among more deprived
patients in 15 of 17 hospitals and higher use among
more deprived patients in the two other hospitals
(range −7.7%-0.6%, fig 6). For surgery there was
lower use among more deprived patients in 15 of 17
hospitals and higher use among deprived patients in
the two other hospitals (range −4.0%-1.2%, fig 7). The
four (of 34) instances that socioeconomic treatment
patterns favoured the more deprived all related to
four different hospitals, and relative differences were
small (figs 6-7). Whether the hospital of diagnosis was
a district general hospital or a referral centre did not
seem to influence hospital level differences (figs 6-7).
Therankcorrelationcoefficient(fordeprivationdiffer-
encesin radiotherapycorrelatedondeprivationdiffer-
ences in surgery) was −0.10 (−0.65 to 0.45, P=0.708);
this indicates that there was no correlation between a hospital ranking “high” for inequality in radiotherapy
with the same hospital ranking “high” for inequality in
surgery use and vice versa. The above observations
strongly indicate that socioeconomic differences in
treatment patterning were general among the studied
hospitals and that, at least in part, the limited instances
of relatively small inverse socioeconomic differences
could be caused by chance.
We also observed less frequent use of either surgery
or radiotherapy in more deprived patients in each one
of the 28 “stratified” models (restricted for different
age,stage,morphology,anddiagnosisperiod)(table 6).
The association between increasing deprivation and
decreasing frequency of use of either treatment was
significant in 25 of the 28 models (in 15 at P<0.001,
in five at P<0.01, and in five at P<0.05). All three
non-significantvaluesrelatedtotheanalysisofthesub-
group of patients for whom we had information on
stage, suggesting loss of power rather than difference
ineffectsize.Inotherwords,stageforstageandagefor
Table 3 |Bivariate association of deprivation (from 1 (affluent) to 5 (most deprived)) with age, diagnosis period, morphology,
and stage in men with prostate cancer. Figures are numbers (percentages) unless stated otherwise
12345 P v a l u e
Age (years):
Mean 72.2 72.9 73.5 74.2 73.9 <0.001*
51-70 3829 (42.7) 3862 (40.2) 3099 (36.4) 2046 (33.4) 675 (34.3)
<0.001†
>70 5148 (57.4) 5735 (59.8) 5411 (63.6) 4073 (66.6) 1293 (65.7)
Diagnosis period:
1995-2000 3728 (41.5) 3991 (41.6) 3682 (43.3) 2766 (45.2) 933 (47.4)
<0.001†
2001-6 5249 (58.5) 5606 (58.4) 4828 (56.7) 3353 (54.8) 1035 (52.6)
Tumour type:
Adenocarcinoma 7730 (86.1) 8082 (84.2) 7104 (83.5) 5084 (83.1) 1628 (82.7)
<0.001†
Unspecified 1247 (13.9) 1515 (15.8) 1406 (16.5) 1035 (16.9) 340 (17.3)
Stage:
Mean stage 2.38 2.45 2.45 2.46 2.45 <0.001*
I-II 7980 (88.9) 8294 (86.4) 7352 (86.4) 5381 (87.9) 1718 (87.3)
0.041†
III-IV 997 (11.1) 1303 (13.6) 1158 (13.6) 738 (12.1) 250 (12.7)
*From analysis of variance.
†From bivariate linear regression models, with deprivation group (1-5) entered as dependent (continuous) variable and age, diagnosis period, tumour
type, and stage binary categories entered as independent variables (four different models, each one using one of four binary variables as
independent variable).
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Fig 3 | Percentage of patients with prostate cancer with
information on stage treated by use of radiotherapy and odds
ratio of radiotherapy by deprivation group (odds ratios and
95% confidence intervals adjusted for age, diagnosis period,
morphology, and stage)
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(odds ratios and 95% confidence intervals adjusted for age,
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either of the two treatments, independently of diagno-
sis period and morphology.
DISCUSSION
Having adjusted for potential socioeconomic differ-
ences in age, diagnosis period, tumour type, and
stage, we found substantial socioeconomic gradients
in use of either radiotherapy or surgery for men with
prostatecancer.Insupplementaryanalyses,wefurther
examined the robustness of the observed socioeco-
nomic differences in treatment patterns by taking into
account clustering of patients or treatment patterns in
different hospitals; by restricting the analysis to
patients for whom we had information on stage; and
by stratifying the analysis to patients of different age,
stage,diagnosisperiod,andtumourtype.Alltheabove
analyses strongly indicated that, on average, more
deprived patients were less likely to undergo surgery
or receive radiotherapy in most hospitals and at any
age, any stage, with any morphology, and during any
studyperiod.Therewasincreasinguseofsurgeryover
time. This probably represents changes during the
study period in availability of surgical expertise, cri-
teria for selecting patients, or patients’ preferences for
surgery.
Strengths
We used a large population based sample of observa-
tionscoveringarelativelylongandrecenttimeperiod.
In addition, we had high quality information on stage
for a substantial proportion of patients, and we have
accountedforpotentialcasemixorvariationinclinical
practicebetweendifferenthospitals.Ourfindingsindi-
cate that stage at diagnosis does not explain the
observed socioeconomic differences in management
and, similarly, that variation between hospitals is also
unlikely to explain such differences.
Comparisons with other studies
We are not aware of other research examining socio-
economic differences in treatment for prostate cancer
that examines potentialclustering at the level of hospi-
tal of diagnosis using multilevel modelling. A recent
UK study also reported higher frequency of surgery
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Fig 5 | Percentage of patients with prostate cancer with stage
information treated by surgery and odds ratio of surgery by
deprivation group (odds ratios and 95% confidence intervals
adjusted for age, diagnosis period, morphology, and stage)
Table 4 |Odds ratio of radiotherapy and surgery use by basic characteristic for all cases of prostate cancer, 1995-2006 (n=35 171) and cases with
information on stage, 1998-2006 (n=15 916). Logistic regression models adjusted for age group, deprivation group, diagnosis period, morphology, and,
where applicable, stage
Variable
Radiotherapy Surgery
All cases With stage information All cases With stage information
Odds ratio (95% CI) Pvalue Odds ratio (95% CI) P value* Odds ratio (95% CI) Pvalue Odds ratio (95% CI) P value*
Age (years):
Continuous 0.51 (0.49 to 0.52) <0.001 0.51 (0.49 to 0.54) <0.001 0.24 (0.22 to 0.25) <0.001 0.22 (0.21 to 0.24) <0.001
51-60 Reference Reference Reference Reference
61-70 1.16 (1.07 to 1.26) <0.001 1.23 (1.09 to 1.39) 0.005 0.45 (0.41 to 0.50) <0.001 0.42 (0.36 to 0.48) <0.001
71-80 0.52 (0.48 to 0.57) <0.001 0.52 (0.46 to 0.59) <0.001 0.04 (0.03 to 0.05) <0.001 0.03 (0.02 to 0.04) <0.001
>80 0.13 (0.12 to 0.15) <0.001 0.13 (0.11 to 0.16) <0.001 0.01 (0.00 to 0.01) <0.001 0.00 (0.00 to 0.01) <0.001
Deprivation:
Continuous 0.92 (0.90 to 0.94) <0.001 0.91 (0.88 to 0.94) <0.001 0.91 (0.87 to 0.94) <0.001 0.92 (0.87 to 0.97) 0.004
1 (affluent) Reference Reference Reference Reference
2 0.93 (0.87 to 1.00) 0.044 0.91 (0.83 to 1.01) 0.071 0.84 (0.74 to 0.94) 0.003 0.85 (0.72 to 1.00) 0.050
3 0.82 (0.77 to 0.88) <0.001 0.77 (0.70 to 0.86) <0.001 0.89 (0.78 to 1.00) 0.057 0.95 (0.80 to 1.13) 0.575
4 0.79 (0.73 to 0.86) <0.001 0.75 (0.67 to 0.85) <0.001 0.76 (0.66 to 0.88) <0.001 0.82 (0.66 to 1.01) 0.057
5 (deprived) 0.71 (0.63 to 0.81) <0.001 0.72 (0.60 to 0.86) <0.001 0.59 (0.46 to 0.76) <0.001 0.56 (0.38 to 0.80) 0.002
Diagnosis period (years):
Continuous 0.94 (0.92 to 0.96) <0.001 0.86 (0.82 to 0.90) <0.001 1.18 (1.12 to 1.24) <0.001 1.02 (0.93 to 1.11) 0.700
1995-7 Reference — Reference —
1998-2000 1.08 (1.00 to 1.16) 0.052 Reference 2.09 (1.76 to 2.49) <0.001 Reference
2001-3 1.12 (1.04 to 1.21) 0.002 1.02 (0.91 to 1.14) 0.72 2.24 (1.89 to 2.66) <0.001 1.14 (0.93 to 1.40) 0.202
2004-6 0.84 (0.78 to 0.91) <0.001 0.78 (0.69 to 0.85) <0.001 2.16 (1.80 to 2.59) <0.001 1.09 (0.90 to 1.32) 0.393
*Adjusted for stage.
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include information on stage at diagnosis.
20 Studies
from Australia also indicated that socioeconomically
disadvantaged patients were less likely to undergo
radicalprostatectomybutdidnotencompasspotential
differences in use of radiotherapy (the other main
treatment).
2122 As in research from the United
States,
19 we observed an association between lower
socioeconomic status and less frequent use of surgery
or radiotherapy. Just over a quarter of all patients who
underwent radical prostatectomy in our study had
stage III disease. This most probably reflects “upsta-
ging” of patients with clinical stage II disease who
were found to have stage III disease at histopathologi-
calexaminationafterradicalprostatectomy.Similaror
slightly higher (compared with those found in our
study) percentages of patients with stage III disease
among hospital series of patients undergoing radical
prostatectomy have been reported both in the US
2324
and the UK.
25
Limitations
Although our lack of information on comorbidity is a
limitation, we would have expected this to negatively
influence eligibility for surgery and not radiotherapy
(which presents no operative risk per se). In fact,
among patients with prostate cancer managed with
active treatment, greater comorbidity (which could
havebeenexpectedtobeassociatedwithhigherdepri-
vation) predicts higher use of radiotherapy.
26 The fact
that socioeconomic differences in use of eithersurgery
or radiotherapy are similar makes it unlikely that
observeddifferencesinuseofsurgeryaresimplyacon-
sequence of socioeconomic differences in comorbid-
ity. In our study population radiotherapy was more
common than surgery use at a ratio of between 5:1 to
3:1, earlier and later in the study, respectively (this is
markedly different than in the US and most European
countries).
192627 Therefore the observed socioeco-
nomic treatment patterning mostly relates to differen-
tial use of radiotherapy. Nevertheless, comorbidity
might influence decision making about any active
management treatment option because oncologists
and surgeons would normally advise radical treat-
ments only in patients with a reasonable life expec-
tancy, when the likely benefits of such treatments
outweigh the side effects that reduce quality of life.
28
More research on how comorbidity status influences
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Fig 6 | Difference (in absolute percentage points) in radiotherapy use between least and most
deprived patients (that is, deprivation groups 1-2 v 3-5) by hospital of diagnosis (A-Q) with
95% confidence intervals. Negative values indicate lower use in most deprived category and
vice versa
Table 5 |Multilevel model, with hospital of diagnosis as cluster level. Odds ratio of radiotherapy and surgery by basic characteristics for all cases of prostate
cancer diagnosed in one of 17 NHS hospital trusts, 1995-2006 (n=29 805), and those patients with information on stage, 1998-2006 (n=14 830). Logistic
regression models adjusted for age group, deprivation group, diagnosis period, morphology, and, where applicable, stage
Variable
Radiotherapy Surgery
All cases With stage information All cases With stage information
Odds ratio (95% CI) Pvalue Odds ratio (95% CI) P value* Odds ratio (95% CI) Pvalue Odds ratio (95% CI) P value*
Age (years):
Continuous 0.48 (0.47 to 0.50) <0.001 0.48 (0.46 to 0.50) <0.001 0.23 (0.21 to 0.24) <0.001 0.22 (0.20 to 0.24) <0.001
51-60 Reference Reference Reference Reference
61-70 1.13 (1.03 to 1.25) 0.009 1.23 (1.08 to 1.39) 0.002 0.45 (0.40 to 0.50) <0.001 0.41 (0.36 to 0.48) <0.001
71-80 0.48 (0.44 to 0.53) <0.001 0.47 (0.41 to 0.54) <0.001 0.04 (0.03 to 0.05) <0.001 0.03 (0.02 to 0.04) <0.001
>80 0.12 (0.10 to 0.14) <0.001 0.11 (0.09 to 0.14) <0.001 0.01 (0.00 to 0.01) <0.001 0.00 (0.00 to 0.01) <0.001
Deprivation:
Continuous 0.94 (0.92 to 0.96) <0.001 0.93 (0.90 to 0.97) <0.001 0.90 (0.86 to 0.95) <0.001 0.88 (0.83 to 0.94) <0.001
1 (affluent) Reference Reference Reference Reference
2 1.02 (0.94 to 1.10) 0.679 0.94 (0.84 to 1.05) 0.251 0.79 (0.69 to 0.90) <0.001 0.74 (0.62 to 0.89) 0.001
3 0.90 (0.83 to 0.98) 0.014 0.86 (0.77 to 0.97) 0.011 0.82 (0.72 to 0.95) 0.006 0.79 (0.66 to 0.96) 0.016
4 0.87 (0.80 to 0.95) 0.002 0.82 (0.72 to 0.94) 0.004 0.75 (0.64 to 0.88) <0.001 0.70 (0.56 to 0.88) 0.002
5 (deprived) 0.75 (0.66 to 0.86) <0.001 0.76 (0.63 to 0.92) 0.006 0.61 (0.47 to 0.81) 0.001 0.50 (0.34 to 0.74) 0.001
Diagnosis period:
Continuous 0.93 (0.90 to 0.95) <0.001 0.89 (0.85 to 0.94) <0.001 1.20 (1.15 to 1.26) <0.001 1.11 (1.01 to 1.22) 0.038
1995-7 Reference — Reference —
1998-2000 1.06 (0.98 to 1.15) 0.164 Reference 2.01 (1.65 to 2.44) <0.001 Reference
2001-3 1.05 (0.97 to 1.14) 0.211 1.00 (0.90 to 1.13) 0.920 2.44 (2.03 to 2.94) <0.001 1.35 (1.07 to 1.69) 0.010
2004-6 0.76 (0.70 t0 0.83) <0.001 0.82 (0.73 to 0.91) 0.001 2.24 (1.87 to 2.69) <0.001 1.33 (1.07 to 1.66) 0.011
*Adjusted for stage.
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prostate cancer would be welcome.
Potential time trends in ascertainment of treatment
status could have biased the findings, but such trends
are unlikely. If there were secular trends in ascertain-
ment of treatment status they would have affected
surgery and radiotherapy similarly, whereas substan-
tial increasing trends in use were observed only for
surgery. Misclassification of treatment status per se is
another source of potential error. Such misclassifica-
tion, however, is unlikely to have been different
between deprivation groups,
29 and, if present, it
wouldhavemadetreatmentpatternsbetweendifferent
groups more similar and would have therefore made
anytruedifferencesin treatmentuse betweendifferent
deprivation groups even smaller than those observed.
A small proportion of patients treated with radio-
therapy were treated with brachytherapy (<1.5% of
all patients and <6% of all patients treated with radio-
therapy), but this cannot explain the observed socio-
economic differences in radiotherapy, as confirmed
by sensitivity analysis (data not shown). We had no
data on use of high intensity focused ultrasound or
cryotherapy, but the use of these procedures, even
recently, seems to be rare
30 and would have been
even rarer during most of the study years (1995-2006).
Although we had no information on stage for a sub-
stantial subset of patients, this limitation has to be seen
Table 6 |Odds ratios* (change in probability of treatment use when moving from deprivation group to one immediately more
deprived) of radiotherapy and surgery in men with prostate cancer, with analysis restricted (stratified) by diagnosis period,
stage, age, and morphology
All cases Staged cases
Odds ratio (95% CI) P value Odds ratio (95% CI) P value
Diagnosis period
Radiotherapy
1995-2000 0.91 (0.88 to 0.94) <0.001 0.88 (0.82 to 0.95) 0.001
2001-6 0.93 (0.90 to 0.95) <0.001 0.91 (0.88 to 0.94) <0.001
Surgery
First subperiod† 0.86 (0.80 to 0.92) <0.001 0.85 (0.74 to 0.99) 0.035
2001-6 0.93 (0.89 to 0.98) 0.003 0.93 (0.88 to 0.99) 0.019
Stage
Radiotherapy
Stages I-II —— 0.92 (0.89 to 0.96) <0.001
Stages III-IV —— 0.88 (0.83 to 0.93) <0.001
Surgery
Stages I-II —— 0.97 (0.91 to 1.03) 0.297
Stages III-IV —— 0.81 (0.72 to 0.91) <0.001
Age (years)
Radiotherapy
≤70 0.94 (0.91 to 0.97) <0.001 0.94 (0.90 to 0.98) 0.007
>70 0.90 (0.87 to 0.92) <0.001 0.87 (0.83 to 0.91) <0.001
Surgery
≤70 0.93 (0.89 to 0.97) <0.001 0.93 (0.88 to 0.99) 0.014
>70 0.73 (0.64 to 0.83) <0.001 0.86 (0.71 to 1.05) 0.137
Morphology
Radiotherapy
Adenocarcinoma 0.92 (0.90 to 0.94) <0.001 0.91 (0.88 to 0.94) <0.001
Unspecified 0.93 (0.87 to 0.99) 0.020 0.88 (0.79 to 0.98) 0.023
Surgery
Adenocarcinoma 0.91 (0.88 to 0.95) <0.001 0.93 ( 0.88 to 0.98) 0.005
Unspecified 0.50 (0.31 to 0.80) 0.004 0.15 (0.02 to 1.00) 0.050
*All odds ratios relate to logistic regression models adjusted for age, diagnosis era, deprivation, morphology, and stage (when available). Values
denote proportion change in odds ratio for one level ordinal increase in deprivation group (for example, from 2nd to 3rd least deprived group).
†Years 1995-2000 for “all patients” and 1998-2000 for “patients with stage information.”
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Fig 7 | Difference (in absolute percentage points) in surgery use between least and most
deprived patients (that is, deprivation groups 1-2 v 3-5) by hospital of diagnosis (A-Q) with
95% confidence intervals. Negative values indicate lower use in the most deprived category
and vice versa
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and period. In addition, deprivationdifferences in sur-
gery or radiotherapy persisted (and were nearly the
same) when we restricted analysis to patients with
information on stage. Given the findings, it is highly
improbable that deprivation differences in the man-
agement of patients without stage information would
have been any different to those observed for “all” as
well as “staged” patients. The fact that deprivation sta-
tus was not a predictor of stage ascertainment makes
such a hypothesis even less probable.
We had no data on ethnic group, which might in
principle be a confounder of socioeconomic
status.
1931 High quality demographic data, however,
indicate that the proportion of individuals belonging
to ethnic minorities in the geographically defined
population of this study was relatively small during
the study period. In the 2001 census (near to the
study period midpoint) only 1.7% of men aged over
65 in the East of England Government Office region
belonged to a minority ethnic group,
32 and of those,
only 0.5% were black or black British, a population
group known to have a higher than average incidence
of prostate cancer.
33 Therefore the observed socioeco-
nomic differences in treatment reflect socioeconomic
treatment patterning among mainly white patients.
We acknowledge that we did not have information
about other dimensions of management, beyond sur-
gery or radiotherapy per se (for example, activity
volume for individual surgeons,
34 radiotherapy dose
andfractionation,andpatients’experience).Therefore
socioeconomic differences in management might be
only partially depicted.
Socioeconomic status can be measured directly by
measuring a person’s income, occupation, or educa-
tion or indirectly by using area based measures of the
characteristics of the population of a small area.
35 We
usedanareabasedmeasurement,incommonwithpre-
vious authoritative UK research.
45 In different coun-
tries, a valid association between area based
socioeconomic status and health outcomes has been
established in the past two decades.
3637 Evidence sug-
gests that both area based and individually measured
socioeconomic status are independently associated
with health outcomes.
38-40 Individual measures of
socioeconomic status also have limitations,
41 and
might be affected by lack of homogeneity within strata
(such as social class or income or education bands).
36
Using an area based indicator of socioeconomic status
might either underestimate or overestimate socioeco-
nomic gradients compared with individual measures,
contextually, for different cancers and indicators.
41
Our area based measures were small and relatively
highly homogeneous (lower super output area),
which substantially improves the methods.
17
Research and policy implications
Whether observed differences in deprivation in use of
surgery and radiotherapy confer a survival advantage
to more affluent groups is debatable.
8 Such an effect is
possible, given some evidence that radical treatment
witheithersurgeryorradiotherapymightconferasur-
vivaladvantage.
4243Itisalsolikely,however,thatsome
of the observed more frequent use of radicaltreatment
in more affluentpatientsmightnot conferany survival
advantage if it relates to relatively less aggressive
tumours. Furthermore, the observed socioeconomic
differences in treatment might reflect true socioeco-
nomicdifferencesinpatients’makingapositivechoice
for either radical or non-radical treatments or socioe-
conomic differences in patient-clinician interactions
about management. Patients of different socioeco-
nomicstatusmighthavedifferentattitudestoaccepting
the risks associated with radical treatments.
28 Decision
makingfortreatmentofprostatecancerisknowntobe
complex
44andatleastinpartpatternedbythepatient’s
lifestyle,educational,anddemographicfactors(suchas
ethnicity).
45-48Explorationofsuchhypothesesthrough
qualitativeresearchmightbewarranted.
19Giventhese
uncertainties, the observed differences in treatment
patterns cannot a priori be assumed to indicate differ-
ences in treatment quality.
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